Cynata (ASX:CYP) strengthens its IP position with new Australian patent - Kalkine Media

Highlights

• Cynata has received a Notice of Acceptance from IP Australia for a patent describing a component of its Cymerus™ MSC platform technology.
• The patent further bolsters the current broad and inclusive IP protection of the Cymerus platform.
• Late last year, Cynata received a Notice of Allowance for US Patent for its MSC platform technology.

Clinical stage cell therapeutics firm Cynata Therapeutics Limited (ASX: CYP) is all set to further strengthen its intellectual property position. The company has received a Notice of Acceptance from IP Australia for a patent application entitled “Method for Treating Allergic Airways Disease (AAD)/Asthma”. It covers Cynata’s unique Cymerus™ mesenchymal stem cell (MSC) platform technology.

The patent application is wholly owned by Cynata and depicts a novel method of use of Cynata’s proprietary Cymerus MSC products in treating diseases of the lungs and airways. It further strengthens the wide and inclusive IP protection of the Cymerus platform. Cynata expects the patent to be granted around mid-March 2023, with an expiration date of 31 August 2038.

IP Australia is the intellectual property office of the Australian government. It directs a Notice of Acceptance to the applicant when it plans to issue a patent.

Management commentary

© 2023 Krish Capital Pty. Ltd., Data and image source: Company Update

As per Cynata, there is compelling commercial opportunity for mesenchymal stem cell (MSC) products. There is growing evidence demonstrating their therapeutic use across a wide range of diseases.

The company is well placed to benefit from the advancement of MSC therapies through its proprietary Cymerus™ platform. It is the most advanced MSC production technology that utilises induced pluripotent stem cells, derived from a single blood donation from a single donor to address the basic challenges related to conventional MSC production methods.

Other significant Notice of Allowances

© 2023 Krish Capital Pty. Ltd., Data source: Company update, Image source: © Jirsak | Megapixl.com

Shares of Cynata closed on Wednesday with an uptick of 3.44% at AU$0.30.